Skip to main content
Premium Trial:

Request an Annual Quote

GCI and Celera Diagnostics to Study Rheumatoid Arthritis

NEW YORK, Jan. 16-Genomics Collaborative and Celera Diagnostics will partner to identify the genetics of rheumatoid arthritis, the two companies said today.


From its Global Repository specimen database, GCI will provide sample sets from rheumatoid arthritis patients and controls, which Celera Diagnostics will analyze for genetic markers.


In the deal, GCI receives an upfront payment and milestone payments on any commercialized products. The companies will share the data generated from these experiments.


The companies did not reveal financial specifics.


GCI is a functional genomics tool and research company in Cambridge, Mass.